Rj. Miller et al., PERCUTANEOUS TRANSPERINEAL CRYOSURGICAL ABLATION OF THE PROSTATE FOR THE PRIMARY-TREATMENT OF CLINICAL STAGE C ADENOCARCINOMA OF THE PROSTATE, Urology, 44(2), 1994, pp. 170-174
Objectives. To assess short-term response rate and local tissue destru
ctive capabilities of cryosurgical ablation of the prostate (CSAP) in
patients with clinical Stage C adenocarcinoma of the prostate. Methods
. A retrospective chart review of 62 patients (mean age, 66 years; ran
ge, 49 to 79 years) treated on an institutional review board approved
protocol at Allegheny General Hospital between June 1990 and December
1993 was performed. Standard follow-up examination included serial pro
state-specific antigens (PSAs), digital rectal examination, and extens
ive biopsies at 3 months after CSAP. Results. Average hospital stay wa
s 2 days and morbidity was minimal. Biopsy findings showed no residual
detectable prostatic tumor in 79% of patients 3 months after 1 CSAP t
reatment and in 94.8% 3 months after 1 or 2 treatments. Mean/median 3-
month post-operative PSAs for patients with negative biopsy findings w
ere 0. 59 +/- 1.66 and 0.10 ng/mL, respectively, compared with 14.0 +/
- 12.1 and 8.90 ng/mL preoperatively. Conclusions. CSAP appears to pro
duce controllable, reproducible local tissue destructive effects. Long
-term (more than 5 years) crude and disease-free survival rates are no
t known for CSAP.